The present invention relates to a compound of Formula (I) wherein Ris hydrogen or lower alkyl； is hydrogen, fluoro, hydroxy or lower alkyl； Ris hydrogen or lower alkyl； R is -CHR-A R ishydrogen, lower alkyl, fluoro, CF, CHOH or cycloalkyl；A is aryl or heteroaryl, which rings are unsubstituted or substituted by (R)o；R may be the same or not when o is more than one, and is heteroaryl, loweralkyl, lower alkoxy, cyano, halogen, lower alkyl substituted by halogen, loweralkoxy substituted by halogen or NRR； o is 1, 2 or 3； R,R are independently hydrogen or lower alkyl； R is loweralkyl； R is lower alkyl, lower alkoxy or halogen； n is 1 or 2； m is 1 or2； or to a pharmaceutically suitable acid addition salt thereof. The inventionincludes all sterioisomeric forms, including individual diastereoisomersand enantiomers of the compound of Formula (I) as well as racemic and non-racemicmixtures thereof. It has been found that the present compounds are high potentialNK-3 receptor antagonists for the treatment of depression, pain, psychosis,Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivitydisorder (ADHD).
